On April 26th, minimally invasive Robot-B (2252.HK) rose sharply and rebounded by more than 18% to HK $27.05, with a total market capitalization of HK $25.9 billion.
The company's swan orthopedic surgery robot has been approved by the State Drug Administration. At present, this product is the only orthopedic surgery robot that is independently developed by Chinese enterprises, has its own intellectual property rights robotic arm, and is approved to be put on the market.
It is reported that the company's dragonfly eye, Tumai surgical robot, swan orthopedic surgical robot three products have been approved by the State Drug Administration on the market.